Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Rotigotine: Dopamine D2/D3 Agonist for Parkinson's Diseas...

    2026-02-13

    Rotigotine: Dopamine D2/D3 Agonist for Parkinson's Disease Research

    Principle and Experimental Setup: Harnessing Rotigotine's Versatility

    Rotigotine, a high-affinity dopamine D2 and D3 receptor agonist, is a cornerstone compound for scientists investigating Parkinson's disease (PD) and dopaminergic signaling pathways. With Ki values of 13 nM for D2 and 0.71 nM for D3, Rotigotine enables precise modulation of these central nervous system targets, supporting both fundamental research and translational studies. Its additional binding to 5-HT1A and adrenergic α2B receptors further broadens its utility in dissecting complex neurotransmitter interactions, making it a preferred dopamine receptor agonist for Parkinson's disease research and a valuable tool for studying the multifaceted neuropharmacology underlying PD and related disorders.

    Supplied by APExBIO with 98.00% purity, Rotigotine (SKU: A3776) is provided as a crystalline solid that is highly soluble in DMSO (≥58 mg/mL) and ethanol (≥25.25 mg/mL), but insoluble in water. For optimal results, it should be stored at -20°C, and solutions are best used immediately after preparation to maintain stability.

    Optimized Experimental Workflows: Step-by-Step Protocol Enhancements

    1. Preparation and Handling

    • Solubilization: Dissolve Rotigotine in DMSO or ethanol to create a stock solution. For cell-based assays, dilute further with culture medium to achieve the desired working concentration, ensuring final DMSO content remains below cytotoxic thresholds (<0.1–0.5% v/v).
    • Aliquoting & Storage: Prepare single-use aliquots and store at -20°C. Avoid repeated freeze-thaw cycles, as prolonged solution storage can reduce efficacy.

    2. In Vitro Cell-Based Assays

    • Model System Selection: Human SH-SY5Y neuroblastoma cells are widely used for dopaminergic studies due to their ability to express dopamine receptors and recapitulate neuronal phenotypes.
    • Exposure Protocol: Treat cells with Rotigotine at empirically optimized concentrations (e.g., 0.1–10 μM) for 24–48 hours. For studies requiring neuroprotection assessment, pre-treat cells before toxin exposure (e.g., 6-OHDA).
    • Endpoints: Assess dopamine receptor activation (e.g., via cAMP assays), cell viability (MTT, LDH), oxidative stress (ROS assays), and neuroprotective markers (tyrosine hydroxylase, alpha-synuclein expression).

    3. In Vivo Animal Models

    • Delivery Innovations: Recent research demonstrates the effectiveness of nose-to-brain delivery of Rotigotine-loaded chitosan nanoparticles, which enhances brain targeting and bioavailability while minimizing peripheral metabolism.
    • Dosing Strategies: In haloperidol-induced PD rat models, intranasal administration of Rotigotine nanoparticles reversed catalepsy and akinesia, and improved behavioral outcomes such as swimming ability.
    • Biochemical Readouts: Monitor endpoints including lactate dehydrogenase (LDH), catalase activities, and expression of key proteins like tyrosine hydroxylase (TH) and alpha-synuclein (SNCA) to evaluate neuroprotective efficacy.

    Advanced Applications and Comparative Advantages

    1. Multi-Receptor Profiling

    Unlike many single-target compounds, Rotigotine’s high affinity for both D2 and D3 receptors, as well as 5-HT1A and adrenergic α2B subtypes, makes it an exceptional dopaminergic signaling pathway modulator. This property enables nuanced studies of cross-talk between dopaminergic, serotonergic, and adrenergic systems, which are increasingly recognized as interrelated in PD pathophysiology and treatment response.

    2. Translational Relevance in Parkinson's Disease Research

    Rotigotine is a benchmark antiparkinsonian activity compound, supported by extensive preclinical and clinical data. The reference study shows that nanoparticle-enabled intranasal delivery leads to significant reductions in alpha-synuclein accumulation and increases in tyrosine hydroxylase expression—two hallmark biomarkers of disease progression and neuronal health. Behavioral improvements in animal models further validate its translational relevance.

    3. Complementary and Extended Literature

    Troubleshooting and Optimization Tips

    Solubility & Solution Stability

    • Solubility Challenges: Rotigotine is insoluble in water; always dissolve in DMSO or ethanol before further dilution. For aqueous applications, ensure DMSO content does not exceed cellular tolerance.
    • Stability: Prepare fresh working solutions for each experiment and avoid storage of diluted solutions. Degradation and loss of activity can occur if solutions are left at room temperature or subjected to repeated freeze-thaw cycles.

    Experimental Controls

    • Include vehicle controls (DMSO or ethanol at equivalent concentrations) to distinguish drug-specific effects from solvent-related artifacts.
    • In cell-based assays for dopamine receptor activity, use positive controls such as quinpirole (D2/D3 agonist) and negative controls (antagonists or receptor knockdown) to validate assay specificity.

    Assay Optimization

    • For cell-based assays for dopamine receptor activity, titrate Rotigotine across a range of concentrations to define dose-response relationships and avoid off-target or cytotoxic effects.
    • Monitor for signs of cytotoxicity with extended exposure, especially in sensitive neuronal cultures. The referenced study reported no cytotoxicity in SH-SY5Y cells after 24-hour exposure at relevant concentrations (Bhattamisra et al., 2020).

    Delivery Innovations

    • For animal models, consider nanoparticle formulations or intranasal routes to bypass first-pass metabolism and enhance brain bioavailability. Chitosan-based nanoparticles have shown high entrapment efficiency and improved pharmacodynamic outcomes.
    • When formulating nanoparticles, optimize particle size (typically <200 nm for nose-to-brain delivery) and entrapment efficiency to maximize central nervous system targeting.

    Future Outlook and Emerging Directions

    As the neuroscience field advances, Rotigotine is poised to remain an indispensable research tool for unraveling the intricacies of dopaminergic, serotonergic, and adrenergic signaling in health and disease. Innovations in delivery—such as nanoparticle carriers and nose-to-brain administration—are expected to further enhance its translational impact, enabling more faithful disease modeling and therapeutic exploration. Data from the reference study (Bhattamisra et al., 2020) highlight the potential for Rotigotine to reduce neurodegenerative markers by 30–50% and improve behavioral outcomes in animal PD models by similar margins.

    Future research is likely to focus on combinatorial approaches, leveraging Rotigotine's unique receptor affinity profile to dissect the interplay between dopamine, serotonin, and adrenergic pathways in PD and beyond. As a trusted supplier, APExBIO ensures high-purity, reliable Rotigotine for cutting-edge neuroscience and pharmacological investigations.

    For further reading on advanced workflow considerations and the latest experimental protocols, see the in-depth reviews and applications outlined in the referenced articles above, which provide complementary, contrastive, and extended perspectives on Rotigotine's role as a next-generation neuroscience receptor agonist.